-- RemeGen (HKG:9995, SHA:688331) booked 328 million yuan in attributable profit for the first quarter of 2026, swinging from a loss of 254.1 million yuan a year earlier, according to a Hong Kong bourse filing Tuesday.
The biopharmaceutical company's Hong Kong shares were down 2% in late morning trade Wednesday.
Earnings per share were 0.58 yuan, compared with a loss of 0.46 year in the prior year period.
Operating revenue jumped 25% year on year to 656.2 million yuan, figures showed.